Synaptogenix (SNPX) Competitors $2.20 -0.10 (-4.35%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNPX vs. ERNA, TRIB, EQ, GELS, NKGN, ME, RLMD, MRKR, SYBX, and NXTCShould you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include Eterna Therapeutics (ERNA), Trinity Biotech (TRIB), Equillium (EQ), Gelteq (GELS), NKGen Biotech (NKGN), 23andMe (ME), Relmada Therapeutics (RLMD), Marker Therapeutics (MRKR), Synlogic (SYBX), and NextCure (NXTC). These companies are all part of the "pharmaceutical products" industry. Synaptogenix vs. Eterna Therapeutics Trinity Biotech Equillium Gelteq NKGen Biotech 23andMe Relmada Therapeutics Marker Therapeutics Synlogic NextCure Synaptogenix (NASDAQ:SNPX) and Eterna Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, community ranking, analyst recommendations, institutional ownership and risk. Is SNPX or ERNA more profitable? Synaptogenix has a net margin of 0.00% compared to Eterna Therapeutics' net margin of -7,513.88%. Eterna Therapeutics' return on equity of 0.00% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets SynaptogenixN/A -42.14% -29.42% Eterna Therapeutics -7,513.88%N/A -117.48% Do analysts prefer SNPX or ERNA? Synaptogenix currently has a consensus price target of $14.00, indicating a potential upside of 533.48%. Given Synaptogenix's stronger consensus rating and higher probable upside, equities analysts clearly believe Synaptogenix is more favorable than Eterna Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Eterna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer SNPX or ERNA? In the previous week, Synaptogenix's average media sentiment score of 1.38 beat Eterna Therapeutics' score of 0.00 indicating that Synaptogenix is being referred to more favorably in the media. Company Overall Sentiment Synaptogenix Positive Eterna Therapeutics Neutral Do insiders and institutionals believe in SNPX or ERNA? 10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 70.6% of Eterna Therapeutics shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 4.5% of Eterna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community believe in SNPX or ERNA? Synaptogenix received 2 more outperform votes than Eterna Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformSynaptogenixOutperform Votes266.67% Underperform Votes133.33% Eterna TherapeuticsN/AN/A Which has more volatility & risk, SNPX or ERNA? Synaptogenix has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, Eterna Therapeutics has a beta of 5.61, suggesting that its share price is 461% more volatile than the S&P 500. Which has higher valuation and earnings, SNPX or ERNA? Synaptogenix has higher earnings, but lower revenue than Eterna Therapeutics. Synaptogenix is trading at a lower price-to-earnings ratio than Eterna Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynaptogenixN/AN/A-$6.04M-$10.08-0.22Eterna Therapeutics$535K26.62-$21.67M-$8.31-0.03 SummarySynaptogenix beats Eterna Therapeutics on 8 of the 15 factors compared between the two stocks. Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNPX vs. The Competition Export to ExcelMetricSynaptogenixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.07M$6.48B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-0.229.0626.7119.71Price / SalesN/A251.50386.13120.55Price / CashN/A65.8538.2534.62Price / Book0.096.456.774.50Net Income-$6.04M$143.98M$3.23B$248.22M7 Day Performance-0.45%2.41%1.80%0.56%1 Month Performance3.71%4.56%11.10%13.17%1 Year Performance-54.24%-2.67%17.11%7.30% Synaptogenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNPXSynaptogenix2.177 of 5 stars$2.21-3.9%$14.00+533.5%-54.2%$3.07MN/A-0.224Positive NewsEarnings ReportGap UpERNAEterna Therapeutics0.7774 of 5 stars$0.22+4.3%N/A-88.9%$13.66M$582,000.00-0.0310Gap UpTRIBTrinity Biotech0.735 of 5 stars$0.76+3.6%N/A-49.9%$13.66M$59.13M-0.33480EQEquillium2.6324 of 5 stars$0.38-0.5%$3.00+685.1%-74.5%$13.65M$41.10M-2.7340GELSGelteqN/A$1.44flatN/AN/A$13.59MN/A0.00N/APositive NewsNKGNNKGen BiotechN/A$0.30+11.1%N/A-85.8%$13.48M$80,000.00-0.06N/APositive NewsGap UpME23andMeN/A$0.50-35.3%N/A-95.3%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeRLMDRelmada Therapeutics4.431 of 5 stars$0.39-2.1%$4.25+989.7%-84.0%$12.95MN/A-0.1410Positive NewsInsider TradeGap DownMRKRMarker Therapeutics4.1018 of 5 stars$1.14flat$13.17+1,055.0%-72.5%$12.90M$6.59M-0.9560Positive NewsAnalyst RevisionGap UpSYBXSynlogicN/A$1.10-2.2%N/A-30.9%$12.87M$8,000.00-0.2680Upcoming EarningsNXTCNextCure3.9566 of 5 stars$0.45+3.3%$3.50+680.4%-69.7%$12.58MN/A-0.2190 Related Companies and Tools Related Companies Eterna Therapeutics Alternatives Trinity Biotech Alternatives Equillium Alternatives Gelteq Alternatives NKGen Biotech Alternatives 23andMe Alternatives Relmada Therapeutics Alternatives Marker Therapeutics Alternatives Synlogic Alternatives NextCure Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNPX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synaptogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SNPX Stock Free SNPX Stock Alerts